Powder: -20°C for 3 years
In solvent: -80°C for 2 years
PD-1/PD-L1-IN-10 is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy.
Description | PD-1/PD-L1-IN-10 is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy. |
Targets&IC50 | PD-1/PD-L1:2.7 nM |
In vitro | PD-1/PD-L1-IN-10 (compound B2) significantly promotes interferongamma secretion in a dose-dependent manner in vitro even at the low concentration of 1 nM[1]. PD-1/PD-L1-IN-10 (compound B2) does not affect cell viability of LLC cells and lymph node T-cells[1]. PD-1/PD-L1-IN-10 (compound B2, 0-100 nM) stabilizes the PD-L1 protein in mouse Lewis lung carcinoma (LLC) cells. Especially, PD-1/PD-L1-IN-10 (compound B2) maintains the PD-L1 stability in a dose-dependent manner at 58 °C. Suggesting that PD-1/PD-L1-IN-10 (compound B2) could enter LLC cells and then directly binds to the PD-L1 protein[1]. |
In vivo | PD-1/PD-L1-IN-10 (compound B2, 5 mg/kg, intragastric gavage) exhibits potent in vivo anticancer efficacy in an LLC-bearing allograft mouse model. PD-1/PD-L1-IN-10 (compound B2) effectively blocks tumor cell proliferation and induces apoptosis in LLC tumor tissues.[1]. |
Molecular Weight | 581.62 |
Formula | C33H31N3O7 |
CAS No. | 2487550-41-2 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 100 mg/mL (171.93 mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PD-1/PD-L1-IN-10 2487550-41-2 Apoptosis Cell Cycle/Checkpoint Immunology/Inflammation PD-1/PD-L1 Lewis T-lymphocyte tumor IFN-γ Inhibitor lung LLC inhibit PD1/PDL1IN10 PD 1/PD L1 IN 10 carcinoma PD-1/PD-L-1-IN-10 inhibitor